Lung Cancer Pill Cuts Risk of Dying by Half in Major Trial

. EGFR is used by normal cells, but certain cancers produce much higher levels of it, which fuels their growth. In 2015, the Food and Drug Administration approved osimertinib to treat advanced non-small cell lung cancers that carried one specific EGFR-related mutation. Since then, AstraZeneca has sought to show that itsover the weekend in the New England Journal of Medicine. It

looks at long-term data from the company’s ADAURA Phase III trial. The trial involved 682 patients diagnosed with early-stage EGFR-mutated NSCLCs who had their tumors completely removed with surgery. The patients were randomized to receive osimertinib or a placebo. The patients had their tumors detected early enough that they could possibly be cured with surgery alone. But these cancers frequently recur and often become fatal. In this trial, however, those taking osimertinib had a noticeably higher chance of survival. Across both the primary analysis and secondary analysis , the drug was found to reduce the risk of dying five years after treatment by 51%.

AstraZeneca plans to release more data showing the effectiveness of using osimertinib in combination with standard chemotherapy to treat advanced EGFR-mutated lung cancers later this year. But outside researchers and advocates are already excited about the drug’s potential to become a frontline treatment for these patients.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lung cancer pill drastically cuts risk of death after surgeryTaking the drug Tagrisso daily after surgery reduced non-small cell lung cancer patients' death risk by more than 50%.
Source: LiveScience - 🏆 538. / 51 Read more »

This Pill Can Halve The Risk of Death After Lung Cancer, Scientists SayA pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results presented on Sunday.
Source: ScienceAlert - 🏆 63. / 68 Read more »

Lung cancer pill found to reduce risk of death after surgery by halfOsimertinib, specially developed to treat the most common type of lung cancer called non-small cell lung cancer, showed promise in 88 percent of patients.
Source: IntEngineering - 🏆 287. / 63 Read more »

AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patientsAstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.
Source: Reuters - 🏆 2. / 97 Read more »

Surviving Lung Cancer Helped Me Embrace the Connection Between Body and MindAfter several HCPs dismissed Susan’s shortness of breath as asthma, she was diagnosed w/ LungCancer & had 2/3 of her right lung removed. Trauma — she says — literally took her breath away. Read how HolisticCare helped heal her body & soul. NCSD
Source: HealthyWomen - 🏆 29. / 68 Read more »

Warning on Use of Sotorasib After ICI in Lung CancerFor patients with non–small cell lung cancer, sotorasib should not be used within 30 days of immune check point inhibitors (ICIs) because of increased toxicity, say French researchers.
Source: Medscape - 🏆 386. / 55 Read more »